The Pharmaceutical Market: Serbia

Date: January 31, 2013
Pages: 100
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P718482399DEN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Serbia
OVERVIEW OF THE PHARMACEUTICAL MARKET IN SERBIA

While the market is small in terms of absolute numbers, relative per capita spending on medicines is expected to improve over the long term. As the country continues its economic convergence with developed Europe, drug consumption is also expected to rise. However, financial inefficiencies within the health insurance system mean that the National Health Insurance Institution ( RZZO ) is unable to always meet its obligations on time, leaving patients to pay for formerly reimbursed medicines or hospitals having to cover the difference .

Headline Expenditure Projections

Pharmaceuticals: RSD75.70bn (US$1.03bn) in 2011 to RSD81.44bn (US$0.92bn) in 2012; +7.6% in local currency terms and -11.0% in US dollar terms.

Healthcare: RSD347.71bn (US$4.74bn) in 2011 to RSD367.32bn (US$4.14bn) in 2012; +5.6% in local currency terms and -12.6% in US dollar terms.

Medical devices: RSD16.64bn (US$223mn) in 2011 to RSD19.98bn (US$223mn) in 2012; +20.1% in local currency terms and -0.7% in US dollar terms.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

SWOT ANALYSIS

      Serbia Pharmaceuticals And Healthcare Industry SWOT
      Serbia Political SWOT
      Serbia Economic SWOT
      Serbia Business Environment SWOT

PHARMACEUTICAL RISK/REWARD RATINGS

      Table: Emerging Europe Regional Pharma Risk/Reward Ratings For Q113
      Rewards
      Risks

MARKET SUMMARY

REGULATORY REGIME

      Table: The Number of Products On The Drugs List
      Corruption In The Healthcare Sector
      Intellectual Property Environment
      Promotion
      Pricing Regime
      Price Developments
      Reimbursement Regime
      Table: Leading Suppliers Of Medicines To RZZO, By Value (RSDmn)
      Table: Cost Of Prescriptions Covered By RZZO By Anatomical Therapeutic Chemical (ATC) Classification (RSD '000)

INDUSTRY DEVELOPMENTS

      Epidemiology
      Communicable Diseases
      Non-Communicable Diseases
      Healthcare Sector
      Table: Major General And Specialised Hospitals
      Healthcare Insurance
      Healthcare Debts
      Clinical Trials
      Medical Devices
      Table: Medical Device Classification In Serbia

INDUSTRY FORECAST SCENARIO

  Overall Market Forecast
      Table: Pharmaceutical Sales Indicators 2008-2016
  Healthcare Market Forecast
      Table: Healthcare Expenditure Indicators 2008-2016
      Table: Healthcare Governmental Indicators 2008-2016
      Table: Healthcare Private Indicators 2008-2016
  Key Growth Factors – Macroeconomic
      Table: Serbia – Economic Activity
  Prescription Drug Market Forecast
      Table: Prescription Drug Sales Indicators 2008-2016
  Patented Drug Market Forecast
      Table: Generic Drug Sales Indicators 2008-2016

© BUSINESS MONITOR INTERNATIONAL LTDPAGE

        Serbia Pharmaceuticals & Healthcare Report Q1 2013
  Generic Drug Market Forecast
      Table: Generic Drug Sales Indicators 2008-2016
  OTC Medicine Market Forecast
      Table: OTC Medicine Sales Indicators 2008-2016
  Pharmaceutical Trade Forecast
      Table: Exports Indicators 2008-2016
      Table: Imports Indicators 2008-2016
      Table: Trade Balance Indicators 2008-2016
  Medical Device Market Forecast
      Table: Medical Devices Sales Indicators 2008-2016
  Other Healthcare Data Forecasts
  Key Risks To BMI’s Forecast Scenario

COMPETITIVE LANDSCAPE

      Investment Climate
      Pharmaceutical Industry
      Table: Companies Involved In The Serbian Pharmaceutical Industry
      Domestic Pharmaceutical Industry
      Domestic Company Activity
      Foreign Pharmaceutical Industry
      Table: Proposed Members Of Serbia’s Pharmaceutical Industry Association
      Foreign Company Activity
      Pharmaceutical Wholesale And Retail

COMPANY MONITOR

      Indigenous Company Profiles
      Hemofarm (Stada)
      Galenika
      Zdravlje Actavis (Watson + Actavis)
      Jugoremedija
      Multinational Company Profiles
      Pfizer
      GlaxoSmithKline
      Novartis
      Sanofi
      Merck & Co
      Krka

DEMOGRAPHIC OUTLOOK

      Table: Serbia's Population By Age Group, 1990-2020 ('000)
      Table: Serbia's Population By Age Group, 1990-2020 (% of total)
      Table: Serbia's Key Population Ratios, 1990-2020
      Table: Serbia's Rural And Urban Population, 1990-2020

GLOSSARY

BMI METHODOLOGY

      How We Generate Our Pharmaceutical Industry Forecasts
      Pharmaceuticals Business Environment Ratings
      Risk/Reward Ratings Methodology
      Ratings System
      Table: Pharmaceutical Business Environment Indicators
      Weighting

TABLE: WEIGHTING OF COMPONENTS

SOURCES
Skip to top


The Pharmaceutical Market: Egypt US$ 1,295.00 Jan, 2013 · 111 pages
The Pharmaceutical Market: Finland US$ 1,295.00 Mar, 2013
The Pharmaceutical Market: France US$ 1,295.00 Jan, 2013 · 107 pages
The Pharmaceutical Market: Germany US$ 1,295.00 Jan, 2013 · 112 pages

Ask Your Question

The Pharmaceutical Market: Serbia
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: